Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) from a sell rating to a hold rating in a research report report published on Thursday morning.

According to Zacks, “Integra exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. On a positive note, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. Overall, in the last three months, Integra Lifesciences has been consistently trading above the broader industry. However, the recent purchase of Derma Sciences and impending buyout of Codman Neurosurgery has made the stock’s valuation stretched.”

IART has been the subject of a number of other reports. Oppenheimer Holdings, Inc. set a $60.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a buy rating in a research note on Saturday, June 24th. UBS AG reaffirmed a buy rating and issued a $60.00 price objective (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Cantor Fitzgerald set a $65.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a buy rating in a research note on Wednesday, July 26th. BidaskClub cut Integra LifeSciences Holdings Corporation from a buy rating to a hold rating in a research note on Monday, July 24th. Finally, Jefferies Group LLC lifted their price objective on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the company a buy rating in a research note on Friday, April 28th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Integra LifeSciences Holdings Corporation has a consensus rating of Buy and a consensus target price of $52.63.

Shares of Integra LifeSciences Holdings Corporation (IART) traded down 0.54% during midday trading on Thursday, hitting $49.68. The company’s stock had a trading volume of 673,094 shares. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of 60.59 and a beta of 0.75. The firm has a 50-day moving average of $53.65 and a 200 day moving average of $46.50. Integra LifeSciences Holdings Corporation has a 12-month low of $37.71 and a 12-month high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business had revenue of $282.16 million during the quarter, compared to analysts’ expectations of $283.58 million. During the same period in the previous year, the firm posted $0.40 earnings per share. The company’s revenue was up 13.2% on a year-over-year basis. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-upgraded-to-hold-by-zacks-investment-research/1464386.html.

In other Integra LifeSciences Holdings Corporation news, Director Stuart Essig sold 135,000 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the completion of the sale, the director now directly owns 2,077,475 shares of the company’s stock, valued at approximately $103,666,002.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Glenn Coleman sold 13,865 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $45.91, for a total value of $636,542.15. Following the sale, the vice president now directly owns 18,519 shares of the company’s stock, valued at $850,207.29. The disclosure for this sale can be found here. Over the last quarter, insiders sold 304,523 shares of company stock valued at $14,812,988. 21.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in IART. BlackRock Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation by 307,726.8% in the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock worth $314,104,000 after buying an additional 7,453,142 shares during the period. Vanguard Group Inc. increased its stake in shares of Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after buying an additional 3,046,488 shares during the period. Champlain Investment Partners LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 125.2% in the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after buying an additional 2,468,145 shares during the period. FMR LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 44.1% in the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after buying an additional 2,329,710 shares during the period. Finally, Janus Capital Management LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 311.6% in the first quarter. Janus Capital Management LLC now owns 2,107,875 shares of the life sciences company’s stock worth $88,803,000 after buying an additional 1,595,705 shares during the period. 89.56% of the stock is owned by institutional investors.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.